不同球囊血管成形术治疗慢性肢体威胁性缺血腘下动脉病变的疗效与安全性比较:系统评价与网络Meta分析
本研究通过网络Meta分析比较普通球囊(POBA)、药物涂层球囊(DCB)和轨道旋切联合普通球囊(OA+POBA)治疗腘下动脉慢性肢体威胁性缺血(CLTI)的效果。纳入8项随机对照试验,结果显示POBA的12个月临床驱动靶病变血运重建率高于DCB(RR 2.11,95%CI 1.33-3.34),DCB未显示安全性担忧。SUCRA提示OA+POBA在靶病变血运重建和全因死亡方面可能最优,但该优势在主要截肢率分析中未持续。
要点
- DCB较POBA显著降低12个月临床驱动靶病变血运重建率(RR 0.47,95%CI 0.30-0.75)。
- DCB未显示统计学显著的安全性担忧。
- SUCRA提示OA+POBA在靶病变血运重建和全因死亡方面可能最优,但主要截肢率分析中优势未持续。
核心结论
- 在腘下动脉CLTI中,DCB的12个月临床驱动靶病变血运重建率显著低于POBA。
- 无统计学显著证据表明DCB增加安全性担忧。
- SUCRA值提示OA+POBA在靶病变血运重建和死亡方面可能优于DCB或POBA,但主要截肢率分析中该优势未持续。
- 需要进一步随机对照试验检验旋切术治疗腘下动脉CLTI的潜在获益。
研究设计与样本
- 系统评价与网络Meta分析,检索Cochrane Central Register of Controlled Trials、Embase和PubMed。
- 纳入8项随机对照试验,涉及3种血管内模态或组合:普通球囊(POBA)、药物涂层球囊(DCB)、轨道旋切联合普通球囊(OA+POBA)。
- 主要结局为疗效(12个月临床驱动靶病变血运重建)和安全性(12个月主要截肢和全因死亡)。
- 采用基于频率学框架的随机效应模型。
主要发现
- 网络Meta分析中,POBA的12个月临床驱动靶病变血运重建率高于DCB(RR 2.11,95%CI 1.33-3.34),亚组分析中该结果仍具统计学显著性(RR 0.47,95%CI 0.30-0.75)。
- 12个月临床驱动靶病变血运重建方面,SUCRA值OA+POBA为72.2(最佳),POBA为8.9(最差)。
- 12个月全因死亡方面,SUCRA值OA+POBA为95.0(最佳),DCB为12.8(最差)。
- 12个月主要截肢方面,SUCRA值POBA为72.0(最佳),DCB为23.0(最差)。
临床怎么用
- 作者指出,当前证据支持临床医生探索和使用DCB与旋切术作为更优治疗。
局限性
- 需要进一步随机对照试验检验旋切术及其他形式旋切治疗腘下动脉CLTI的潜在获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal endovascular method to treat infrapopliteal chronic limb-threatening ischemia (CLTI) remains to be determined, given the limitations of stent use in infrapopliteal artery disease. We performed a network meta-analysis (NWM) of randomized controlled trials (RCTs) to simultaneously compare the outcomes of different balloon angioplasty procedures for infrapopliteal artery lesions in CLTI patients. METHODS: We searched the Cochrane Central Register of Controlled Trials, Embase, and PubMed. 8 eligible RCTs involving 3 endovascular modalities or combinations (plain old balloon angioplasty [POBA], drug-coated balloon [DCB], orbital atherectomy plus plain old balloon angioplasty [OA+POBA]) were included. Primary outcomes were efficacy (12-month clinically driven target lesion revascularization [CDTLR]) and safety (12-month major amputation and all-cause mortality). We used random-effects models based on the frequentist framework. RESULTS: Plain old balloon angioplasty had a higher 12-month CDTLR rate than DCB (relative risk [RR]: 2.11, confidence interval [CI]: 1.33, 3.34) in the NWM and this result was still statistically significant (RR: 0.47, CI: 0.30, 0.75) in subgroup analyses. According to the SUCRA value, in terms of 12-month CDTLR, OA+POBA was considered the best treatment (SUCRA=72.2), while POBA was considered the worst treatment (SUCRA=8.9). In terms of 12-month all-cause mortality, OA+POBA was considered the best treatment (SUCRA=95.0), while DCB was considered the worst treatment (SUCRA=12.8). In terms of 12-month major amputation, POBA was considered the best treatment (SUCRA=72.0), while DCB was considered the worst treatment (SUCRA=23.0). CONCLUSIONS: In infrapopliteal CLTI disease, DCB showed a significantly lower 12-month CDTLR in comparison to POBA. There is no statistically significant evidence to suggest that DCB raises safety concerns. The SUCRA values of OA+POBA indicate that it might offer a superior treatment option compared to DCB or POBA in terms of CDTLR and mortality. This advantage, however, was not sustained when major-amputation rates were analyzed. Consequently, further RCTs are required to examine the potential benefits of OA and other forms of atherectomy for managing infrapopliteal CLTI disease.Clinical ImpactThe findings of this study provide further evidence for the safety of DCB in the application of infrapopliteal CLTI disease and suggest preliminary benefits of atherectomy. These results are likely to encourage further research and application of these treatment modalities in managing infrapopliteal CLTI.POBA has been a traditional approach for treating infrapopliteal artery disease. The current evidence supports clinicians in exploring and utilizing DCB and atherectomy as better treatments.We focused on the performance of different balloon angioplasty procedures in infrapopliteal CLTI, considering the characteristics of infrapopliteal CLTI.
引用
- Guo Z, Guo J, Wu S, et al. Comparative Efficacy and Safety of Different Balloon Angioplasty Procedures for Infrapopliteal Artery Lesions in Chronic Limb-Threatening Ischemia Patients: A Systematic Review and Network Meta-Analysis. J Endovasc Ther. 2024. PMID: 39578965. doi:10.1177/15266028241292954
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。